Maurizio Federico

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 12

Top Topics

High Efficiency

Respiratory Syndrome Coronavirus

Immune Response

Protein Protein

Top Venues

Journal of immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Maurizio Federico
The Limitations of Current T Cell-Driven Anticancer Immunotherapies Can Be Overcome with an Original Extracellular-Vesicle-Based Vaccine Strategy. Vaccines 11 (12) (2023)
Maurizio Federico
The Limitations of Current T Cell-Driven Anticancer Immunotherapies Can Be Overcome with an Original Extracellular-Vesicle-Based Vaccine Strategy. Vaccines 11 (12) (2023)
Flavia Ferrantelli, Francesco Manfredi, Chiara Chiozzini, Patrizia Leone, Katherina Pugliese, Massimo Spada, Antonio Di Virgilio, Andrea Giovannelli, Mauro Valeri, Andrea Cara, Zuleika Michelini, Mauro Andreotti, Maurizio Federico
SARS-CoV-2-Specific CD8 + T-Cells in Blood but Not in the Lungs of Vaccinated K18-hACE2 Mice after Infection. Vaccines 11 (9) (2023)
Francesco Manfredi, Chiara Chiozzini, Flavia Ferrantelli, Patrizia Leone, Katherina Pugliese, Massimo Spada, Antonio Di Virgilio, Andrea Giovannelli, Mauro Valeri, Andrea Cara, Zuleika Michelini, Mauro Andreotti, Maurizio Federico
Antiviral effect of SARS-CoV-2 N-specific CD8 + T cells induced in lungs by engineered extracellular vesicles. NPJ vaccines 8 (1) (2023)
Flavia Ferrantelli, Chiara Chiozzini, Francesco Manfredi, Patrizia Leone, Massimo Spada, Antonio Di Virgilio, Andrea Giovannelli, Massimo Sanchez, Andrea Cara, Zuleika Michelini, Maurizio Federico
Strong SARS-CoV-2 N-Specific CD8 + T Immunity Induced by Engineered Extracellular Vesicles Associates with Protection from Lethal Infection in Mice. Viruses 14 (2) (2022)
Francesco Manfredi, Chiara Chiozzini, Flavia Ferrantelli, Patrizia Leone, Andrea Giovannelli, Massimo Sanchez, Maurizio Federico
Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein. Vaccines 10 (7) (2022)
Maurizio Federico
How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease? International journal of molecular sciences 23 (18) (2022)
Maurizio Federico
Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production. Journal of immunology research 2022 (2022)
Maurizio Federico
Virus-Induced CD8+ T-Cell Immunity and Its Exploitation to Contain the SARS-CoV-2 Pandemic. Vaccines 9 (8) (2021)
Flavia Ferrantelli, Chiara Chiozzini, Francesco Manfredi, Andrea Giovannelli, Patrizia Leone, Maurizio Federico
Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs. Vaccines 9 (3) (2021)
Flavia Ferrantelli, Francesco Manfredi, Chiara Chiozzini, Patrizia Leone, Andrea Giovannelli, Eleonora Olivetta, Maurizio Federico
Long-Term Antitumor CD8+ T Cell Immunity Induced by Endogenously Engineered Extracellular Vesicles. Cancers 13 (9) (2021)
Chiara Chiozzini, Francesco Manfredi, Flavia Ferrantelli, Patrizia Leone, Andrea Giovannelli, Eleonora Olivetta, Maurizio Federico
The C-Terminal Domain of Nefmut Is Dispensable for the CD8+ T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. Vaccines 9 (4) (2021)